Public Employees Retirement System of Ohio grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 53,279 shares of the biopharmaceutical company’s stock after acquiring an additional 223 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Regeneron Pharmaceuticals were worth $18,381,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Ostrum Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $108,000. Icon Wealth Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $112,000. Signaturefd LLC raised its stake in shares of Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 198 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $159,000. Finally, Summit Trail Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 22,971.8% in the 1st quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 165,627 shares in the last quarter. Institutional investors own 66.88% of the company’s stock.

In other news, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $360.00, for a total value of $720,000.00. Following the transaction, the director now owns 14,000 shares in the company, valued at approximately $5,040,000. The disclosure for this sale can be found here. Insiders have sold 184,722 shares of company stock worth $71,990,260 over the last ninety days. 12.42% of the stock is owned by insiders.

Shares of Regeneron Pharmaceuticals stock opened at $390.28 on Friday. The firm has a market cap of $42.17 billion, a PE ratio of 23.71, a P/E/G ratio of 1.30 and a beta of 1.23. The company has a current ratio of 3.62, a quick ratio of 2.92 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $477.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.60 by $0.85. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.17 earnings per share. equities research analysts predict that Regeneron Pharmaceuticals Inc will post 19.4 EPS for the current fiscal year.

A number of research firms have recently commented on REGN. SunTrust Banks set a $344.00 price objective on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, July 2nd. BidaskClub raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. TheStreet raised Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, July 25th. Robert W. Baird downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, August 3rd. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $340.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $407.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.